Iovance Biotherapeutics, Inc.
IOVA
$3.89
-$0.15-3.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 28.64% | 12.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 28.64% | 12.52% | |||
| Cost of Revenue | 12.04% | -32.10% | |||
| Gross Profit | 50.67% | 781.33% | |||
| SG&A Expenses | 5.34% | -8.34% | |||
| Depreciation & Amortization | 5.66% | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.92% | -9.51% | |||
| Operating Income | 18.16% | 21.11% | |||
| Income Before Tax | 23.42% | 14.60% | |||
| Income Tax Expenses | 107.65% | -220.98% | |||
| Earnings from Continuing Operations | 21.20% | 18.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.20% | 18.27% | |||
| EBIT | 18.16% | 21.11% | |||
| EBITDA | 21.57% | 22.64% | |||
| EPS Basic | 29.52% | 24.90% | |||
| Normalized Basic EPS | 33.49% | 25.82% | |||
| EPS Diluted | 29.52% | 24.90% | |||
| Normalized Diluted EPS | 33.49% | 25.82% | |||
| Average Basic Shares Outstanding | 11.79% | 8.83% | |||
| Average Diluted Shares Outstanding | 11.79% | 8.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||